Mariana C. Stern, PhD, discusses the biggest gaps identified in the 2026 AACR Cancer Disparities Progress Report and what oncologists can do to combat them.
News|Articles|February 26, 2025
- Vol. 26/No. 4
- Volume 26
- Issue 4
Tips for Tomorrow: What 4 Experts Wish They Knew Earlier About ADCs
Author(s)Megan Hollasch
Fact checked by: Caroline Seymour
Clinicians with years of ADC therapy experience provide insights on the drug class and what is most important to keep in mind when treating patients.
Advertisement
Advertisement
Although antibody-drug conjugates (ADCs) have been approved in select tumor types for years now, the 2024 tumor-agnostic approval of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) for select patients has provided the first ever ADC option in many cancers.1
Related to this article
Breast cancer experts share insights on how recently approved indications for 3 ADCs will affect clinical practice.
Daniel Boiarsky, MD, and William Phillips, MD, discuss findings from studies that they presented during the OncLive National Fellows Forum: Lung Cancer.
A surgical team from Huntsman Cancer Institute at the University of Utah has performed the first robotic mastectomy in the Mountain West.
Jill Gilbert, MD, discusses the journey of lifelong learning in hematology/oncology.
Antibodies directed against TNFR2, a regulator in the TME that promotes tumor cell proliferation, have shown promise in T-cell lymphoma and ovarian cancer.
Maurie Markman, MD, discusses conflicts of interest in cancer care.
In an OncLive Peer Exchange, experts discussed the evolving treatment landscape in CLL, spanning frontline selection to emerging next-generation agents.
Advertisement
Advertisement